ImmunityBio partners with Biopharma, Cigalah to launch Anktiva in Saudi Arabia

ImmunityBio (IBRX) announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch Anktiva in Saudi Arabia and, over time, across the broader MENA region. “We’re pleased to partner with two of the largest healthcare and distribution companies to launch to ANKTIVA to patients in Saudi Arabia and, across the broader Middle East and North Africa region,” said Richard Adcock, president and CEO of ImmunityBio. Under the agreement, Biopharma and Cigalah Healthcare will support the commercialization and distribution of Anktiva in two indications: In combination with Bacillus Calmette-Guerin, or BCG, for patients with BCG-unresponsive non-muscle invasive bladder cancer, or NMIBC, carcinoma in situ, with or without papillary disease; and in combination with a checkpoint inhibitor for patients with metastatic non-small cell lung cancer.